Literature DB >> 28866768

Providers' Response to Clinical Decision Support for QT Prolonging Drugs.

Sunita Sharma1, J Martijn Bos2, Robert F Tarrell3, Gyorgy J Simon4, Bruce W Morlan3, Michael J Ackerman2,5,6,7, Pedro J Caraballo8.   

Abstract

Commonly used drugs in hospital setting can cause QT prolongation and trigger life-threatening arrhythmias. We evaluate changes in prescribing behavior after the implementation of a clinical decision support system to prevent the use of QT prolonging medications in the hospital setting. We conducted a quasi-experimental study, before and after the implementation of a clinical decision support system integrated in the electronic medical record (QT-alert system). This system detects patients at risk of significant QT prolongation (QTc>500ms) and alerts providers ordering QT prolonging drugs. We reviewed the electronic health record to assess the provider's responses which were classified as "action taken" (QT drug avoided, QT drug changed, other QT drug(s) avoided, ECG monitoring, electrolytes monitoring, QT issue acknowledged, other actions) or "no action taken". Approximately, 15.5% (95/612) of the alerts were followed by a provider's action in the pre-intervention phase compared with 21% (228/1085) in the post-intervention phase (p=0.006). The most common type of actions taken during pre-intervention phase compared to post-intervention phase were ECG monitoring (8% vs. 13%, p=0.002) and QT issue acknowledgment (2.1% vs. 4.1%, p=0.03). Notably, there was no significant difference for other actions including QT drug avoided (p=0.8), QT drug changed (p=0.06) and other QT drug(s) avoided (p=0.3). Our study demonstrated that the QT alert system prompted a higher proportion of providers to take action on patients at risk of complications. However, the overall impact was modest underscoring the need for educating providers and optimizing clinical decision support to further reduce drug-induced QT prolongation.

Entities:  

Keywords:  Clinical decision support systems; Electrocardiogram; Medical informatics; Medical order entry systems; Prolonged QT interval; Torsades de pointes

Mesh:

Year:  2017        PMID: 28866768     DOI: 10.1007/s10916-017-0803-7

Source DB:  PubMed          Journal:  J Med Syst        ISSN: 0148-5598            Impact factor:   4.460


  19 in total

1.  Prescribers' responses to alerts during medication ordering in the long term care setting.

Authors:  James Judge; Terry S Field; Martin DeFlorio; Jane Laprino; Jill Auger; Paula Rochon; David W Bates; Jerry H Gurwitz
Journal:  J Am Med Inform Assoc       Date:  2006-04-18       Impact factor: 4.497

Review 2.  What evidence supports the use of computerized alerts and prompts to improve clinicians' prescribing behavior?

Authors:  Angela Schedlbauer; Vibhore Prasad; Caroline Mulvaney; Shobha Phansalkar; Wendy Stanton; David W Bates; Anthony J Avery
Journal:  J Am Med Inform Assoc       Date:  2009-04-23       Impact factor: 4.497

3.  Impact of clinical decision support preventing the use of QT-prolonging medications for patients at risk for torsade de pointes.

Authors:  Atsushi Sorita; J Martijn Bos; Bruce W Morlan; Robert F Tarrell; Michael J Ackerman; Pedro J Caraballo
Journal:  J Am Med Inform Assoc       Date:  2014-10-16       Impact factor: 4.497

Review 4.  The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?

Authors:  Carla Meyer-Massetti; Christine M Cheng; Bradley A Sharpe; Christoph R Meier; B Joseph Guglielmo
Journal:  J Hosp Med       Date:  2010-04       Impact factor: 2.960

5.  Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.

Authors:  Barbara J Drew; Michael J Ackerman; Marjorie Funk; W Brian Gibler; Paul Kligfield; Venu Menon; George J Philippides; Dan M Roden; Wojciech Zareba
Journal:  Circulation       Date:  2010-02-08       Impact factor: 29.690

6.  Don't fuel the fire: decreasing intravenous haloperidol use in high risk patients via a customized electronic alert.

Authors:  Jonathan Michael Pell; Dora Cheung; Michael A Jones; Ethan Cumbler
Journal:  J Am Med Inform Assoc       Date:  2014-06-13       Impact factor: 4.497

7.  Institution-wide QT alert system identifies patients with a high risk of mortality.

Authors:  Kristina H Haugaa; J Martijn Bos; Robert F Tarrell; Bruce W Morlan; Pedro J Caraballo; Michael J Ackerman
Journal:  Mayo Clin Proc       Date:  2013-04       Impact factor: 7.616

8.  Prolonged QTc intervals on admission electrocardiograms: prevalence and correspondence with admission electrolyte abnormalities.

Authors:  Houtan Golzari; Neal V Dawson; Ted Speroff; Charles Thomas
Journal:  Conn Med       Date:  2007-08

9.  QT interval disturbances in hospitalized elderly patients.

Authors:  Emilia Lubart; Refael Segal; Alexandra Yearovoi; Aharon Fridenson; Yehuda Baumoehl; Arthur Leibovitz
Journal:  Isr Med Assoc J       Date:  2009-03       Impact factor: 0.892

10.  The prevalence and factors associated with QTc prolongation among emergency department patients.

Authors:  Michael W Seftchick; Peter H Adler; Margaret Hsieh; Allan B Wolfson; Steven T C Chan; Benjamin W Webster; Gregory D Frattaroli
Journal:  Ann Emerg Med       Date:  2009-05-06       Impact factor: 5.721

View more
  11 in total

1.  Development of a risk model for predicting QTc interval prolongation in patients using QTc-prolonging drugs.

Authors:  Anita N Bindraban; José Rolvink; Florine A Berger; Patricia M L A van den Bemt; Aaf F M Kuijper; Ruud T M van der Hoeven; Aukje K Mantel-Teeuwisse; Matthijs L Becker
Journal:  Int J Clin Pharm       Date:  2018-07-26

Review 2.  Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias.

Authors:  J R Giudicessi; M J Ackerman; M Camilleri
Journal:  Neurogastroenterol Motil       Date:  2018-02-14       Impact factor: 3.598

3.  Effect of Replacing Vendor QTc Alerts with a Custom QTc Risk Alert in Inpatients.

Authors:  Steven Stettner; Sarah Adie; Sarah Hanigan; Michael Thomas; Kristen Pogue; Christopher Zimmerman
Journal:  Appl Clin Inform       Date:  2022-01-05       Impact factor: 2.342

4.  Conundrum of Clinical QTc Monitoring.

Authors:  Marek Malik
Journal:  Drug Saf       Date:  2022-08-26       Impact factor: 5.228

5.  Development of a Risk Score for QT Prolongation in the Intensive Care Unit Using Time-Series Electrocardiogram Data and Electronic Medical Records.

Authors:  Tae Young Kim; Byung Jin Choi; Yeryung Koo; Sukhoon Lee; Dukyong Yoon
Journal:  Healthc Inform Res       Date:  2021-07-31

Review 6.  Sources of QTc variability: Implications for effective ECG monitoring in clinical practice.

Authors:  Katerina Hnatkova; Marek Malik
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-11-24       Impact factor: 1.468

7.  Content Validation of an Algorithm for the Assessment, Management and Monitoring of Drug-Induced QTc Prolongation in the Psychiatric Population.

Authors:  Monica Zolezzi; Athar Elhakim; Waad M Elamin; Shorouk Homs; Doaa E Mahmoud; Iman A Qubaiah
Journal:  Neuropsychiatr Dis Treat       Date:  2021-11-19       Impact factor: 2.570

8.  Assessing Prescriber Behavior with a Clinical Decision Support Tool to Prevent Drug-Induced Long QT Syndrome.

Authors:  Katy E Trinkley; Jonathan M Pell; Dario D Martinez; Nicola R Maude; Gary Hale; Michael A Rosenberg
Journal:  Appl Clin Inform       Date:  2021-03-10       Impact factor: 2.342

9.  Influence of heart rate correction formulas on QTc interval stability.

Authors:  Irena Andršová; Katerina Hnatkova; Martina Šišáková; Ondřej Toman; Peter Smetana; Katharina M Huster; Petra Barthel; Tomáš Novotný; Georg Schmidt; Marek Malik
Journal:  Sci Rep       Date:  2021-07-12       Impact factor: 4.996

Review 10.  Managing drug-induced QT prolongation in clinical practice.

Authors:  Rani Khatib; Fatima R N Sabir; Caroline Omari; Chris Pepper; Muzahir Hassan Tayebjee
Journal:  Postgrad Med J       Date:  2020-10-29       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.